Jazz Pharmaceuticals (JAZZ) Other Non-Current Assets (2010 - 2026)

Jazz Pharmaceuticals' Other Non-Current Assets history runs 17 years deep, the most recent figure standing at $94.7 million for Q1 2026.

• In Q1 2026, Other Non-Current Assets rose 952.34% year-over-year to $94.7 million; the TTM figure through Mar 2026 stood at $94.7 million (up 952.34% YoY), while the FY2025 annual figure was $99.0 million, down 13.52% from the prior year.
• Other Non-Current Assets was $94.7 million for Q1 2026 at Jazz Pharmaceuticals, down from $99.0 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $114.5 million in Q4 2024 to a low of $5.7 million in Q2 2024.
• Historically, Other Non-Current Assets has averaged $49.5 million across 5 years, with a median of $55.1 million in 2022.
• The sharpest annual moves came in 2024 and 2026: Other Non-Current Assets plunged 90.97% in 2024, then surged 952.34% in 2026.
• A 5-year view of Other Non-Current Assets shows it stood at $55.1 million in 2022, then advanced by 22.35% to $67.5 million in 2023, then soared by 69.69% to $114.5 million in 2024, then dropped by 13.52% to $99.0 million in 2025, then declined by 4.34% to $94.7 million in 2026.
• The last three Other Non-Current Assets figures came in at $94.7 million (Q1 2026), $99.0 million (Q4 2025), and $103.1 million (Q3 2025), per Business Quant data.